BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

BioPharma

8 APAC Assets That Went Global The Out-Licensing Class of 2025 to 2026

Business development teams across the region keep arriving at the same question, phrased slightly differently each time. What did a comparable asset, at a ...

July 29, 2026 | Analysis

HoneyNaps Expands Global CRO Services with AI-Powered Sleep Analytics Platform

Strengthens specialized AI-powered sleep data analysis services for global pharmaceutical, medical device, and healthcare companies Targets the rapidly ...

July 29, 2026 | News

7 Countries Competing to Be the Region’s Next Biomanufacturing Hub

A siting decision for a biomanufacturing facility is one of the most expensive commitments a company makes, and it is made against a fifteen to twenty year...

July 27, 2026 | Analysis

Top 26 Companies Leading Sustainable Biopharma Practices in 2026

Sustainability has stopped being a side conversation in the pharmaceutical industry. In 2026 it sits at the centre of how the sector defines leadership. Th...

July 23, 2026 | Analysis

From Capacity to Capability: The New Race to Lead ASEAN Biomanufacturing

ASEAN is entering a new phase of biopharmaceutical manufacturing, where simply building more capacity will no longer guarantee competitiveness. As ...

July 17, 2026 | Expert Insight

Takeda Backs Indonesia's Plasma Ambitions with US$30 Million Investment to Build ASEAN's First Integrated Plasma Ecosystem

Ministry of Health of the Republic of Indonesia Grants Plasma Fractionation License, Enabling Takeda to Collect and Fractionate Plasma as Part of Multi...

July 14, 2026 | News

West Launches Synchrony™ Prefillable Syringe System for Biologics and Vaccines in Southeast Asia

West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, announced the av...

July 10, 2026 | News

Vectors, Plasmids and the CGT Trap: APAC's Cell and Gene Therapy Ambitions Face an Upstream Bottleneck

THE GATE The choke point nobody puts on the slide Somewhere in the region this quarter, a cell-and-gene developer has everything the pitch deck promised....

July 03, 2026 | Analysis

PharmaResearch Expands U.S. Footprint with CG USA Acquisition to Boost REJURAN Cosmetics Growth

Acquisition strengthens local manufacturing and logistics capabilities as REJURAN Cosmetics expands across Sephora, Amazon and Canada, ...

July 01, 2026 | News

After the Drug Substance, the Real Squeeze: APAC's Aseptic Fill-Finish Gap

For most of the last decade, the anxiety in Asia-Pacific biomanufacturing pointed upstream. The conversation was about bioreactor volume — how many t...

June 22, 2026 | Analysis

Agility or Corner-Cutting? Asia's Accelerated-Approval Gamble

On 1 April 2026, Japan's Pharmaceuticals and Medical Devices Agency did something no other major medicines regulator had done before it: from that date, ev...

June 17, 2026 | Analysis

Formation Bio Doses First Participant in Phase I Trial of Lynk’s CNS-Penetrant TYK2 Inhibitor

Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on autoimmune and inflammatory diseas...

June 12, 2026 | News

When America Builds a Wall: Who Inherits China’s Displaced Biotech Work?

When President Trump signed the FY2026 National Defense Authorization Act on December 18, 2025, the biopharmaceutical industry finally got the law it had s...

June 02, 2026 | Analysis | By arcilla.fran@biopharmaapac.com

Lupin Limited Enters China Market With Approval For Paediatric Oseltamivir Oral Suspension

Global pharmaceutical company Lupin Limited announced that China's National Medical Products Administration has approved the shortened marketing authorizat...

May 25, 2026 | News

Stay Connected